Morgan Stanley Previews Earnings For Cardinal Health, Quest Diagnostics

Loading...
Loading...

Morgan Stanley previewed earnings for Cardinal Health Inc CAH and Quest Diagnostics Inc DGX.

Analysts led by Ricky R. Goldwasser felt that when Cardinal Health reports, the “key focus will be on the impact of the Red Oak generic sourcing agreement, capital deployment plans, and outlook for the remainder of FY15.”

The firm estimated FY2Q2015 EPS at $1.08, below consensus of $1.10.

Morgan Stanley maintained an Overweight rating and $86 price target.

Cardinal Health reports earnings on January 29. Heading into the release, the stock was moving higher and recently traded at $86.47, up 2.09 percent.

Goldwasser was going to look for “color on capital deployment and M&A in the wake" of the Laboratory Corp. of America Holdings LH acquisition o Covance Inc. CVDwhen Quest Diagnostics reports earnings.

The firm estimated FY4Q14 EPS at $1.04, in line with consensus.

Morgan Stanley maintained an Underweight rating and $69 price target.

Quest Diagnostics reports earnings on January 29. Heading into the release, the stock had gained over 5 percent over the past month and recently traded at $71.40, up 0.11 percent.

date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsMorgan StanleyRicky R. Goldwasser
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...